117 related articles for article (PubMed ID: 38015548)
1. Mutational and expressional association of the PIK3CA gene with the risk of breast cancer in the Pakistani population.
Abbasi SA; Khan R; Ahmed MN; Hussain K; Riaz A; Mansoor Q; Qayyum M; Mehmood Baig R
Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):1-8. PubMed ID: 38015548
[TBL] [Abstract][Full Text] [Related]
2. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
[TBL] [Abstract][Full Text] [Related]
3. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
[TBL] [Abstract][Full Text] [Related]
4. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
5. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Karakas B; Colak D; Kaya N; Ghebeh H; Al-Qasem A; Hendrayani F; Toulimat M; Al-Tweigeri T; Park BH; Aboussekhra A
Cancer Biol Ther; 2013 Oct; 14(10):888-96. PubMed ID: 23982433
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
9. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
[TBL] [Abstract][Full Text] [Related]
10. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients.
Tong L; Yang XX; Liu MF; Yao GY; Dong JY; Ye CS; Li M
Asian Pac J Cancer Prev; 2012; 13(11):5599-603. PubMed ID: 23317280
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
13. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
[TBL] [Abstract][Full Text] [Related]
14. Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.
Lasota J; Felisiak-Golabek A; Wasag B; Kowalik A; Zięba S; Chłopek M; Wang ZF; Coates T; Kopczynski J; Gozdz S; Sarlomo-Rikala M; Miettinen M
Mod Pathol; 2016 Mar; 29(3):275-82. PubMed ID: 26796526
[TBL] [Abstract][Full Text] [Related]
15. A novel PIK3CA hotspot mutation in Isfahanian breast cancer patients.
Gharbi S; Faghihi M; Tavassoli M
Cancer Invest; 2011 May; 29(4):313-7. PubMed ID: 21345071
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.
Tharin Z; Richard C; Derangère V; Ilie A; Arnould L; Ghiringhelli F; Boidot R; Ladoire S
Sci Rep; 2023 Mar; 13(1):4467. PubMed ID: 36934165
[TBL] [Abstract][Full Text] [Related]
17. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
Dumont AG; Dumont SN; Trent JC
Chin J Cancer; 2012 Jul; 31(7):327-34. PubMed ID: 22640628
[TBL] [Abstract][Full Text] [Related]
18. Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations.
Sivakumar S; Jin DX; Rathod R; Ross J; Cantley LC; Scaltriti M; Chen JW; Hutchinson KE; Wilson TR; Sokol ES; Vasan N
Clin Cancer Res; 2023 Mar; 29(6):1125-1136. PubMed ID: 36595567
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
Cizkova M; Cizeron-Clairac G; Vacher S; Susini A; Andrieu C; Lidereau R; Bièche I
PLoS One; 2010 Dec; 5(12):e15647. PubMed ID: 21209903
[TBL] [Abstract][Full Text] [Related]
20. PIK3R1 underexpression is an independent prognostic marker in breast cancer.
Cizkova M; Vacher S; Meseure D; Trassard M; Susini A; Mlcuchova D; Callens C; Rouleau E; Spyratos F; Lidereau R; Bièche I
BMC Cancer; 2013 Nov; 13():545. PubMed ID: 24229379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]